Upload
karthik-balachandran
View
89
Download
0
Embed Size (px)
Citation preview
Learning objectives• What is post transplant diabetes ?• How is it different from other types of diabetes ?• What are the challenges in prevention,diagnosis and management ?• Effect of transplant on glucose metabolism/diabetes• Effect of diabetes on transplant
Terminology – no longer NODAT• 2003 – first international consensus guidelines on NODAT• 2013 – consensus guidelines revised
1. NODAT to PTDM2. Timing – PTDM to be diagnosed only after discharge, on stable
immunosuppression,without acute illness,rejection or infection3. HbA1c >6.5 % can be used to diagnose, but should not be used to screen for
PTDM , especially in the first year after transplantion
Incidence
Shivaswamy, Vijay; Boerner, Brian; Larsen, Jennifer (2015): Post-transplant diabetes mellitus: Causes, treatment, and impact on outcomes. In Endocrine reviews, pp. er20151084.
Prevalence• 10 to 15% in literature *• 50 to 60% in JIPMER
Jenssen, Trond; Hartmann, Anders (2015): Emerging treatments for post-transplantation diabetes mellitus. In Nature reviews. Nephrology 11 (8), pp. 465–477.
Risk factors
Sharif, Adnan; Cohney, Solomon (2015): Post-transplantation diabetes—state of the art. In The Lancet Diabetes & Endocrinology.
Risk factors
Shivaswamy, Vijay; Boerner, Brian; Larsen, Jennifer (2015): Post-transplant diabetes mellitus: Causes, treatment, and impact on outcomes. In Endocrine reviews, pp. er20151084.
Pathophysiology
Immunosuppression and CV profile
Role of stress/ inflammation• Ongoing graft vs host response• Acute vs chronic rejection• Reduced renal function• Greater incidence of chronic infections• HCV - ? Through hepatic inflammation• CMV
• Leucocyte mediated damage to β cells • Proinflammatory cytokines• Prophylaxis does not prevent PTDM
Others• Vitamin D deficiency• RCT on vitamin D supplementation going on
• Statins• Class effect vs drug effect – atorvastatin > fluvastatin
Diagnosis• Commonly used – FPG – poor sensitivity• HbA1c – reliability issues in the first year• OGTT – cumbersome, timing of OGTT• Gold standard• Reproducibility issues• Reversal – upto 20% over 5 years
• Novel approaches• Afternoon or late evening blood glucose• OGTT for those with HbA1c between 5.7 to 6.4 %
How is it different?
Effect of diabetes on transplant• Heart transplant – does not affect survival, increases hypertension,
renal failure, rejection and infection• Liver transplation – increases HCV infection and fibrosis, affects short
term survival but minimal effect on long term survival• Renal – decreases survival and increases rejection• PTDM better than pre existing DM
Effect of diabetes on transplant
Management• Goals not clearly established• Prevention • Treatment
Risk factors
Sharif, Adnan; Cohney, Solomon (2015): Post-transplantation diabetes—state of the art. In The Lancet Diabetes & Endocrinology.
In patient treatment considerations
Renal impairment and diabetes drugs
OHAs – potential considerations
CV risk mitigation• BP control• KDOQI - <140/80 mm Hg• KDIGO - <130 / 80 mm Hg• ACE inhibitor / ARB – first line, prefer ARB in hyperkalemia• Diuretics are second line• CCBs – drug interaction with immunosuppressants
• Dyslipidemia management• Statins – weaker evidence base• Sirolimus and everolimus – severe hypertriglyceridemia• Statins + fibrates / niacin – rhabdomyolisis / liver injury in patients taking CNI
Others• Eye care and feet care same as routine diabetes• Annual influenza vaccine• 5 yearly Pneumococcal vaccine• Tacrolimus /sirolimus induced oligospermia / hypogonadism• Contraception / prepregnancy counseling
Summary• PTDM prevalence depends on definition – substantial burden• Pitfalls in diagnosis – wait till at least 3 months after transplant• Preventive advice important, risk prediction algorithms not well
developed yet• ?tackle non traditional risk factors
• Metformin, Linagliptin and insulin • Drug interactions – increase toxicity / decrease efficacy of
immunosuppressive agents• Team work